TET1 and breast cancer: In 2022, Umeh-Garcia et al38 utilized CRISPR/dCas9 to demonstrate that TET1-mediated demethylation, combined with transcriptional activation of leucine-rich repeat and immunoglobulin-like domain 1 (LRIG1), could reduce breast cancer cell viability, offering a promising avenue for targeted breast cancer therapies.